PHARMACEUTICAL PRODUCT DEVELOPMENT INC Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent
PHARMACEUTICAL PRODUCT DEVELOPMENT INC reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent of $35.62 million for the 3-month period ending 2011-09-30, per its 10-Q filed 2011-11-02.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromContinuingOperations · last filed 2011-11-02
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2011-09-30 was $35.62M, a 6.28% decline year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2011-06-30 was $45.41M, a 92.75% increase year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2011-03-31 was $37.37M, a 104.39% increase year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2010-12-31 was $47.48M, a 90.53% increase year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2010 was $127.33M, a 16.01% decline from fiscal 2009.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2009 was $151.61M, a 19.34% decline from fiscal 2008.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2008 was $187.95M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 3 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 6 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 9 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2011-09-30 | $35.62M 10-Q · filed 2011-11-02 | $81.03M derived: sum of 2 quarters · filed 2011-11-02 | $118.40M 10-Q · filed 2011-11-02 | $165.88M derived: sum of 4 quarters · filed 2011-11-02 |
| 2011-06-30 | $45.41M 10-Q · filed 2011-08-04 | $82.78M 10-Q · filed 2011-08-04 | $130.26M derived: sum of 3 quarters · filed 2011-08-04 | $168.27M derived: sum of 4 quarters · filed 2011-11-02 |
| 2011-03-31 | $37.37M 10-Q · filed 2011-05-03 | $84.85M derived: sum of 2 quarters · filed 2011-05-03 | $122.85M derived: sum of 3 quarters · filed 2011-11-02 | $146.41M derived: sum of 4 quarters · filed 2011-11-02 |
| 2010-12-31 | $47.48M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $85.48M derived: sum of 2 quarters · filed 2011-11-02 | $109.05M derived: sum of 3 quarters · filed 2011-11-02 | $127.33M 10-K · filed 2011-02-25 |
| 2010-09-30 | $38.00M 10-Q · filed 2011-11-02 | $61.56M derived: sum of 2 quarters · filed 2011-11-02 | $79.85M 10-Q · filed 2011-11-02 | $104.77M derived: sum of 4 quarters · filed 2011-11-02 |
| 2010-06-30 | $23.56M 10-Q · filed 2011-08-04 | $41.84M 10-Q · filed 2011-08-04 | $66.77M derived: sum of 3 quarters · filed 2011-08-04 | $106.86M derived: sum of 4 quarters · filed 2011-08-04 |
| 2010-03-31 | $18.28M 10-Q · filed 2011-05-03 | $43.20M derived: sum of 2 quarters · filed 2011-05-03 | $83.30M derived: sum of 3 quarters · filed 2011-05-03 | $124.75M derived: sum of 4 quarters · filed 2011-05-03 |
| 2009-12-31 | $24.92M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $65.02M derived: sum of 2 quarters · filed 2011-02-25 | $106.47M derived: sum of 3 quarters · filed 2011-02-25 | $151.61M 10-K · filed 2011-02-25 |
| 2009-09-30 | $40.10M 10-Q · filed 2010-11-05 | $81.55M derived: sum of 2 quarters · filed 2010-11-05 | $126.69M 10-Q · filed 2010-11-05 | |
| 2009-06-30 | $41.45M 10-Q · filed 2010-08-06 | $86.58M 10-Q · filed 2010-08-06 | ||
| 2008-12-31 | $187.95M 10-K · filed 2011-02-25 |